Benlysta Autoinjector Approval Transforming Pediatric Lupus Nephritis Management
GSK’s Benlysta autoinjector gains FDA nod for pediatric lupus nephritis, enabling at-home treatment.
GSK’s Benlysta autoinjector gains FDA nod for pediatric lupus nephritis, enabling at-home treatment.
SINTX acquires SiNAPTIC assets, targeting the $1.3B foot and ankle fusion implant market.
PathPresenter wins FDA clearance for digital pathology viewer, advancing primary diagnosis and LIS integration.
FDA De Novo nod for TISSIUM’s COAPTIUM CONNECT: a new era in sutureless nerve repair.
Revolution inks $2B flexible deal with Royalty Pharma to fund RAS(ON) inhibitors in cancer.
ART5803 targets NMDA receptor autoantibodies, advancing precision therapy for autoimmune encephalitis.
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
ENHERTU Phase 3 trial launches for first-line endometrial therapy targeting HER2-expressing tumors.
AI partnership targets rare bone disease affecting 1 in 6,000 patients.
ZEISS expands retinal diagnostic capabilities in China with CLARUS 700 ultra-widefield imaging system approval.